GlassScriptPhysician profile
Gary James Avallone
NPI 1457300261
$5,270.19
in general payments reported to CMS, 2019-2025
19 companies · $952 in 2025
The $952 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $922 · 2021: $917 · 2022: $590 · 2023: $619 · 2024: $735 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Entertainment: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.65 |
| Entertainment | $262.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,359.42 | 2019-2024 | Clareon, Precision 7 |
| Optos, INC. | $535.27 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $492.36 | 2025 | |
| Allergan, INC. | $480.89 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $410.47 | 2019-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $364.22 | 2020-2025 | Cequa |
| Sight Sciences, INC. | $250.09 | 2020-2025 | Tearcare System |
| Rxsight INC | $236.10 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $212.34 | 2023-2025 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $184.48 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $124.46 | 2021 | |
| Dompe US, INC. | $124.37 | 2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $118.36 | 2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.54 | 2019 | |
| Oyster Point Pharma, INC. | $81.88 | 2023 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $72.28 | 2020 | |
| Alimera Sciences, INC. | $61.87 | 2019 | |
| Abbvie INC. | $41.05 | 2022 | |
| Glaukos Corporation | $20.74 | 2023 | Photrexa Cross-Linking Kit, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Avallone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.